For the Inventor, By the Inventor

Enter assignee name

Université Paris—sud

USPTO Granted Patents = 100

% Expired Patents = 36.0

CIPO Patents = 9

EPO Patents = 85

Forward Citations = 180

Loading Chart...

Loading Chart...

317 inventors (with patents filed for the assignee):

William Vainchenker (9 out of 13 patents)

Nicole Casadevall (6 out of 7 patents)

Jean-Pierre Le Couedic (5 out of 6 patents)

4. Olivier Christophe (5 out of 13 patents)

5. Jean-Daniel Brion (4 out of 15 patents)

6. Petrus Lenting (4 out of 7 patents)

7. Eli Hatchwell (3 out of 35 patents)

8. Peggy S Eis (3 out of 34 patents)

9. Sylvia Cohen-Kaminsky (3 out of 5 patents)

10. Gilles Bru-Mercier (3 out of 5 patents)

11. Mouad Alami (3 out of 11 patents)

12. Samir Messaoudi (3 out of 6 patents)

13. Jamila Faivre (3 out of 3 patents)

14. Franck Viguie (3 out of 4 patents)

15. Olivier Bernard (3 out of 8 patents)

Core Competencies:

Bleeding Disorders

Cancer Treatments

Imaging Technologies

Antibodies

Genetic Testing

Microfluidics

Viral Infections

Hematopoietic Neoplasms

Polypeptides

Neurodegenerative Disorders

Drug Resistance

Electromagnetic Devices

100 patents: Sort by Forward Citations

1. 12559569 - METHODS OF TREATING BLEEDING DISORDERS BY ADMINISTRATION OF CHIMERAS COMPRISING ANTI-VON WILLEBRAND FACTOR ANTIBODIES AND CLOTTING FACTORS (2026-02-24),

2. 12129487 - Method to obtain lymphoid progenitors (2024-10-29),

3. 12105254 - Element for covering the projection aperture of a heads-up display device (2024-10-01),

4. 11597777 - Antibodies for the prevention or the treatment of bleeding episodes (2023-03-07),

5. 11484569 - Polypeptide for use in the protection of oxygen sensitive gram-positive bacteria (2022-11-01),

6. 11376245 - Dizocilpine derivatives as peripheral NMDA receptor antagonists (2022-07-05),

7. 11285133 - 2- or 3-imidazolines as carbapenemases inhibitors (2022-03-29),

8. 11235174 - Minibeam radiotherapy device (2022-02-01),

9. 11221341 - Process for in vitro diagnosis of hepatic disorders (2022-01-11),

10. 11203788 - TET2 as a diagnostic and pronostic marker in hematopoietic neoplasms (2021-12-21),

11. 11162100 - Identification of a JAK2 mutation in polycythemia vera (2021-11-02),

12. 11085921 - Electronic nose or tongue sensors (2021-08-10),

13. 11046657 - Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines (2021-06-29),

14. 11014871 - 'Multi-target' compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer (2021-05-25),

15. 10955654 - Imaging device and method (2021-03-23),

Company Overview

Université Paris—Sud, located in Orsay, France, is a prominent institution specializing in biomedical innovations. The university focuses on advancing research in critical areas such as bleeding disorders, cancer treatments, and imaging technologies. Its expertise extends to the development of antibodies, genetic testing methodologies, and microfluidics, addressing complex challenges in viral infections and hematopoietic neoplasms. The institution fosters a collaborative environment that encourages interdisciplinary research, contributing significantly to the global biomedical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

100 Patents

#1 in Orsay

#275 in France

#7,784 in the World

Université Paris—sud

Forward Citations = 180

317 inventors:

William Vainchenker (9 out of 13 patents)

Nicole Casadevall (6 out of 7 patents)

Jean-Pierre Le Couedic (5 out of 6 patents)

4. Olivier Christophe (5 out of 13 patents)

5. Jean-Daniel Brion (4 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Université Paris—sud. Retrieved from https://idiyas.com/company/universite-paris-sud

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…